Working to close the TB diagnostics and treatment gap

Tuberculosis is both preventable and curable, so why does it remain one of the world's biggest threats? In this guest column Janssen's Wim Parys, and Claudia Denkinger of FIND, weigh in on how development practitioners can collaborate to modernize and scale up TB diagnosis and care.

The views in this opinion piece do not necessarily reflect Devex's editorial views.

About the authors

  • Wim Parys

    Wim Parys is the head of research and development at Janssen's global public health group. He was development head of Janssen’s infectious diseases and vaccines therapeutic area and he led the discovery and development of other medicines for HIV, hepatitis C, multidrug-resistant tuberculosis and respiratory viral diseases. He held several R&D positions and developed a drug for Alzheimer’s disease and three innovative HIV drugs. He obtained his medical degree from the Katholieke Universiteit Leuven, Belgium.
  • Claudia Denkinger

    Dr. Claudia Denkinger is the head of tuberculosis and hepatitis program at FIND. She completed her medical school training and doctoral thesis in immunology at the Julius-Maximilians University in Wuerzburg, Germany. She trained in internal medicine at the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston and also was the chief medical resident there. She has worked in nongovernmental organizations in HIV and tuberculosis care in South Africa and South America. She holds a faculty appointment in the division of infectious disease at the BIDMC, Harvard Medical School.